ZymeTx: flu management program could be catching

Published By Datamonitor

Zimmer: big advances through tiny holes

Zimmer has released positive preliminary results for its two-incision minimally invasive hip arthroplasty system, and also plans to open a training facility teaching surgeons how to implant these systems. But while the system can radically reduce recovery time, it involves an extremely difficult technique that most orthopaedic surgeons are unlikely to adopt.

Published By Datamonitor

Wyeth: Big Pharma continues its shopping spree

The current economic environment has paved the way for leading pharmaceutical firms to sweep in and buy up smaller players, highlighted by Wyeth's potential acquisition of Crucell and Merck & Co's strategy to aggressively look for targets in 2009. An increasing number of pharmaceutical majors are likely to use this approach to strengthen their biologic portfolios and access novel pipeline drugs.

Published By Datamonitor

Women's mental health: no easy thinking, no easy solutions

Published By Datamonitor

Waxman leads the call for greater transparency on Part D drug prices

Following the recent hearing of the House Oversight and Government Reform Committee, its chair Rep. Waxman, has indicated that he is pushing for greater clarity on the cost of drugs through Medicare Part D. This step adds increasing pressure on the government's decision to contract out Part D to private insurance companies, as Datamonitor analyst Dr Mark Belsey discovers

Published By Datamonitor

US pharmaceuticals: caregiver needs provide commercial opportunities

Despite the role of the caregiver in patient welfare gaining an ever greater profile, the group remains largely overlooked by the marketing campaigns of the pharmaceutical industry. This is slowly starting to change however, as pharma companies recognize the impact that the caregiver audience can have on a company's bottom line.

Published By Datamonitor

US healthcare reform: a double-edged sword

The US House of Representatives has passed legislation paving the way for major healthcare system reform designed to substantially decrease the number of individuals without health insurance. Despite its potential benefits, Datamonitor believes that the reform is a mixed blessing for the pharmaceutical industry as cost-containment pressures are set to intensify in the long term.

Published By Datamonitor

UK: criticism mounts over NHS reform but pharmaceutical firms may benefit

The UK coalition government is facing legal action from public services trade union UNISON over plans to shake up the National Health Service in a bid to find efficiency savings. However, the proposed reforms could benefit pharmaceutical companies, with patients gaining access to drugs previously blocked by the health service's cost watchdog.

Published By Datamonitor

UK healthcare: NHS changes will have an impact - eventually

The grossly underfunded NHS is finally receiving some help. The additional funds will be used for modernization, financial incentives, paying debts, and increasing staff - all necessary steps to improve patient care. While this budget increase is only the first step in a 20-year program, any rise in NHS funding is good news for staff, patients - and medical device companies.

Published By Datamonitor

UK healthcare: encouraging patient empowerment

Published By Datamonitor